Ying Liu

Cooley advised Harbour BioMed (HBM Holdings, HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in oncology and immunology, on its HK$517.75 million placement of new shares under general mandate.

Cooley advised Akeso (Hong Kong Stock Exchange: 9926.HK), a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing and commercializing innovative medicines that address global medical needs, on its HK$3.97 billion (US$509.01 million) placement of shares.

Cooley advised MetaLight Inc., a China-domiciled company specializing in big data analytics, on its HK$242.35 million initial public offering (IPO).

Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.

Cooley advised Harbour BioMed (HBM Holdings, HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in oncology and immunology, on its share subscription agreement with AstraZeneca.